Research ArticleAccepted Article
Opioid Use in Patients with Ankylosing Spondylitis is Common in the United States: Outcomes of a Retrospective Cohort Study
Victor S. Sloan, Anna Sheahan, Jeffrey L. Stark and Robert Y. Suruki
The Journal of Rheumatology January 2019, jrheum.180972; DOI: https://doi.org/10.3899/jrheum.180972
Victor S. Sloan
From UCB Pharma, Raleigh, NC, USA; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; UCB Pharma, Smyrna, GA, USA. UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from UCB perspective, the data presented in the publication are scientifically, technically and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content. All listed authors are employees of UCB Pharma. In addition, VSS is a holder of stock and options in UCB Pharma, and AS, JLS and RYS are shareholders in UCB Pharma. Address correspondence to Victor S. Sloan, UCB Pharma, 8010 Arco Corporate Dr, Raleigh, NC 27617, USA. Phone: +1 919-767-1650. Email: Victor.Sloan@ucb.com
Anna Sheahan
From UCB Pharma, Raleigh, NC, USA; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; UCB Pharma, Smyrna, GA, USA. UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from UCB perspective, the data presented in the publication are scientifically, technically and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content. All listed authors are employees of UCB Pharma. In addition, VSS is a holder of stock and options in UCB Pharma, and AS, JLS and RYS are shareholders in UCB Pharma. Address correspondence to Victor S. Sloan, UCB Pharma, 8010 Arco Corporate Dr, Raleigh, NC 27617, USA. Phone: +1 919-767-1650. Email: Victor.Sloan@ucb.com
Jeffrey L. Stark
From UCB Pharma, Raleigh, NC, USA; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; UCB Pharma, Smyrna, GA, USA. UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from UCB perspective, the data presented in the publication are scientifically, technically and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content. All listed authors are employees of UCB Pharma. In addition, VSS is a holder of stock and options in UCB Pharma, and AS, JLS and RYS are shareholders in UCB Pharma. Address correspondence to Victor S. Sloan, UCB Pharma, 8010 Arco Corporate Dr, Raleigh, NC 27617, USA. Phone: +1 919-767-1650. Email: Victor.Sloan@ucb.com
Robert Y. Suruki
From UCB Pharma, Raleigh, NC, USA; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; UCB Pharma, Smyrna, GA, USA. UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from UCB perspective, the data presented in the publication are scientifically, technically and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content. All listed authors are employees of UCB Pharma. In addition, VSS is a holder of stock and options in UCB Pharma, and AS, JLS and RYS are shareholders in UCB Pharma. Address correspondence to Victor S. Sloan, UCB Pharma, 8010 Arco Corporate Dr, Raleigh, NC 27617, USA. Phone: +1 919-767-1650. Email: Victor.Sloan@ucb.com
Article Figures & Data
Additional Files
Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Opioid Use in Patients with Ankylosing Spondylitis is Common in the United States: Outcomes of a Retrospective Cohort Study
Victor S. Sloan, Anna Sheahan, Jeffrey L. Stark, Robert Y. Suruki
The Journal of Rheumatology Jan 2019, jrheum.180972; DOI: 10.3899/jrheum.180972